
Starling Oncology, Inc.: updates and filings
Price
$3.29
November 19, 2026Market cap $326M
What Ploutos Investor adds for Starling Oncology
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 52% since Nov 5, 2026, when the 10-Q these figures come from was filed ($6.70 then, $3.20 on Nov 18, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 5, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
September 2026
August 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 13, 2026One of its securities removed from an exchange (usually a matured note)Form25-NSE
- Nov 12, 2026Regulation FD disclosure (amendment)Form8-K/A
- Nov 12, 2026Regulation FD disclosureForm8-K
- Nov 6, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Results of operationsForm8-K
- Sep 2, 2026Officer or director changeForm8-K
- Aug 21, 2026Material agreement entered, new material financial obligationForm8-K
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Aug 3, 2026Amended articles or bylaws, Regulation FD disclosureForm8-K
- Jul 7, 2026Material agreement entered, new material financial obligation, unregistered sale of shares, Regulation FD disclosureForm8-K
- Jun 18, 2026Shareholder voteForm8-K
- May 22, 2026Material cybersecurity incidentForm8-K
- May 15, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- May 7, 2026Results of operationsForm8-K
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 30, 2026Additional annual meeting materialFormDEFA14A
- Apr 30, 2026Annual meeting proxy statementFormDEF 14A
- Apr 28, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Mar 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 13, 2026Regulation FD disclosureForm8-K
- Mar 12, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 12, 2026Results of operationsForm8-K
- Feb 23, 2026Officer or director change, Regulation FD disclosureForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 13, 2026 | 25-NSE | One of its securities removed from an exchange (usually a matured note) | Document |
| Nov 12, 2026 | 8-K/A | Regulation FD disclosure (amendment) | Document |
| Nov 12, 2026 | 8-K | Regulation FD disclosure | Document |
| Nov 6, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations | Document |
| Sep 2, 2026 | 8-K | Officer or director change | Document |
| Aug 21, 2026 | 8-K | Material agreement entered, new material financial obligation | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Aug 3, 2026 | 8-K | Amended articles or bylaws, Regulation FD disclosure | Document |
| Jul 7, 2026 | 8-K | Material agreement entered, new material financial obligation, unregistered sale of shares, Regulation FD disclosure | Document |
| Jun 18, 2026 | 8-K | Shareholder vote | Document |
| May 22, 2026 | 8-K | Material cybersecurity incident | Document |
| May 15, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 30, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 30, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 28, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Mar 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 13, 2026 | 8-K | Regulation FD disclosure | Document |
| Mar 12, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 12, 2026 | 8-K | Results of operations | Document |
| Feb 23, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 14, 2020.
The full analysis
What do Starling Oncology's filings show?
The filings are where every one of Starling Oncology's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.